TSS
INKT icon

Two Sigma Securities’s MiNK Therapeutics INKT Stock Holding History

Two Sigma Securities’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,194
Closed -$8.95K – 2383
2024
Q3 		$8.95K Buy
+1,194
New +$10.1K ﹤0.01% 2611

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Securities's INKT Position: Q4 2024 in Review

Two Sigma Securities sold out of MiNK Therapeutics (INKT) in Q4 2024, closing a stake of 1,194 shares — an estimated $8.95K sold.

Two Sigma Securities first reported a position in INKT in Q3 2024 and held it in 1 quarter. The position peaked at $8.95K in Q3 2024. 21 funds tracked by Wall St. Rank hold INKT as of Q4 2024.

  • Two Sigma Securities reported no remaining MiNK Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Securities sold 1,194 MiNK Therapeutics shares in Q4 2024, an estimated $8.95K.
  • Two Sigma Securities first reported a position in MiNK Therapeutics in Q3 2024 and held it in 1 quarter.
  • Two Sigma Securities's MiNK Therapeutics position peaked at $8.95K in Q3 2024.
  • 21 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q4 2024.

Based on Two Sigma Securities's 13F filing for Q4 2024, filed 14 Feb 2025.